The study followed patients for two years after surgery and found the OsteoSponge SC procedure could address defects associated with subchondral bone pathology, including failed microfracture procedures and other treatment modalities. Bacterin is the only company in the market with a product specifically addressing subchondral bone repair in treating these defects with clinical evidence to support the technique.
The study included 12 adults with previously failed microfracture treatment who had talus defects. The patients underwent a malleolar osteotomy with OsteoSponge SC allograft. The patients reported significant pain and disability improvements after two years.
OsteoSponge SC is approved as a bone void filler to treat bony defects in the subchondral region of articulating joins.
More articles on orthopedic devices:
Orthocell raises $8M in oversubscribed IPO
Smith & Nephew introduces lesser toe repair system
Bacterin’s new common stock public offering: 5 quick facts
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
